Price
$1.12
Decreased by -1.75%
Dollar volume (20D)
798.15 K
ADR%
8.04
Earnings report date
Nov 5, 2024
Shares float
128.63 M
Shares short
9.59 M [7.46%]
Shares outstanding
167.80 M
Market cap
191.29 M
Beta
0.78
Price/earnings
N/A
20D range
1.03 1.36
50D range
1.03 1.40
200D range
1.03 2.85

Atai Life SciencesN. V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders.

Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression.

The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology.

In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder.

Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression.

ATAI Life SciencesN. V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Aug 6, 24 -0.36
Decreased by -71.43%
-0.16
Decreased by -125.00%
May 15, 24 -0.17
Increased by +19.05%
-0.18
Increased by +5.56%
Mar 28, 24 -0.12
Increased by +57.14%
-0.16
Increased by +25.00%
Nov 14, 23 -0.28
Decreased by -27.27%
-0.20
Decreased by -40.00%
Aug 10, 23 -0.21
Increased by +12.50%
-0.21
May 11, 23 -0.21
Increased by +12.50%
-0.21
Mar 24, 23 -0.28
Increased by +54.84%
-0.23
Decreased by -21.74%
Nov 10, 22 -0.22
Decreased by -4.76%
-0.23
Increased by +4.35%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 24 273.00 K
Increased by +58.72%
-57.31 M
Decreased by -73.45%
Decreased by -20.99 K%
Decreased by -9.28%
Mar 31, 24 0.00
Decreased by -100.00%
-26.71 M
Increased by +19.83%
Decreased by N/A%
Decreased by N/A%
Dec 31, 23 18.00 K
Decreased by -52.63%
-18.29 M
Increased by +59.64%
Decreased by -101.62 K%
Increased by +14.80%
Sep 30, 23 87.00 K
Increased by +262.50%
44.24 M
Increased by +232.99%
Increased by +50.86 K%
Increased by +136.69%
Jun 30, 23 172.00 K
Increased by +1.18%
-33.04 M
Decreased by -7.08%
Decreased by -19.21 K%
Decreased by -5.84%
Mar 31, 23 37.00 K
Increased by +N/A%
-33.32 M
Decreased by -4.25%
Decreased by -90.06 K%
Decreased by N/A%
Dec 31, 22 38.00 K
Decreased by -83.48%
-45.32 M
Increased by +49.00%
Decreased by -119.27 K%
Decreased by -208.66%
Sep 30, 22 24.00 K
Decreased by -90.98%
-33.27 M
Decreased by -6.78%
Decreased by -138.62 K%
Decreased by -1.08 K%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY